Therapeutic effects of dopamine D1/D2 receptor agonists on detrusor hyperreflexia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned Parkinsonian cynomolgus monkeys

Journal of Pharmacology and Experimental Therapeutics

Volumn 286, Issue 1, 1998, Pages 228-233

  Yoshimura, Naoki ^a,c   Mizuta, Eiji ^b   Yoshida, Osamu ^a   Kuno, Sadako ^b  

^a KYOTO UNIVERSITY   (Japan)

^b UTANO NATIONAL HOSPITAL   (Japan)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; 6 METHYL 8 (1,2,4 TRIAZOL 1 YLMETHYL)ERGOLINE MALEATE; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; BROMOCRIPTINE; DOPAMINE 1 RECEPTOR BLOCKING AGENT; DOPAMINE 1 RECEPTOR STIMULATING AGENT; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE 2 RECEPTOR STIMULATING AGENT; PERGOLIDE; SULPIRIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLADDER CAPACITY; CONTROLLED STUDY; DETRUSOR DYSSYNERGIA; DRUG ANTAGONISM; MALE; MICTURITION; MONKEY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

ANIMALS; BROMOCRIPTINE; DOPAMINE AGONISTS; ERGOLINES; MACACA FASCICULARIS; MALE; MPTP POISONING; PARKINSON DISEASE, SECONDARY; PERGOLIDE; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D2; REFLEX; TRIAZOLES; URINARY BLADDER; URINATION;

EID: 0031820993     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. 1 agonist SKF 82958 in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned parkinsonian cynomolgus monkeys. J Pharmacol Exp Ther 273:309-314.
2. 2 receptors in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned parkinsonian cynomolgus monkeys. Jpn J Pharmacol 67:117-124.
3. Albanese A, Jenner P, Marsden CD and Stephenson JD (1988) Bladder hyperreflexia induced in marmosets by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neurosci Lett 87:46-50.
4. Aranda B and Cramer P (1993) Effects of apomorphine and L-dopa on the parkinsonian bladder. Neurourol Urodyn 12:203-209.
5. Baik J-H, Picetti R, Saiardi A, Thiriet G, Dierich A, Depaulis A, Le Meur M and Borrelli E (1995) Parkinson-like locomotor impairment in mice laking dopamine D2 receptors. Nature 377:424-428.
6. Berger Y, Blaivas JG, Delarocha ER and Salinas JM (1987) Urodynamic findings in Parkinson's disease. J Urol 138:836-838.
7. Calne DB (1993) Treatment of Parkinson's disease. N Engl J Med 329:1021-1027.
8. Civelli O, Bunzow JR and Grandy DK (1993) Molecular diversity of the dopamine receptors. Annu Rev Pharmacol Toxicol 32:281-307.
9. De Groat WC, Booth AM and Yoshimura N (1993) Neurophysiology of micturition and its modification in animal models of human disease, in The Autonomic Nervous System: Nervous Control of the Urogenital System (Maggi CA, ed) vol 3, pp 227-290, Horwood Academic Publishers, London, UK
10. Di Chiara G, Morelli M and Consolo S (1994) Modulatory functions of neurotransmitters in the striatum: ACh/dopamine/NMDA interactions. Trends Neurosci 17: 228-233.
11. Factor SA, Sanchez-Ramos JR and Weiner WJ (1988) Parkinson's disease: an open label trial of pergolide in patients failing bromocriptine therapy. J Neurol Neurosurg Psychiatry 51:529-533.
12. 2 receptors. Life Sci 49:925-930.
13. Goetz CG (1985) Chronic agonist therapy for Parkinson's disease: A 5-year study of bromocriptine and pergolide. Neurology 35:749-751.
14. Hornykiewicz O and Kish SJ (1986) Biochemical pathophysiology of Parkinson's disease. Adv Neurol 45:19-34.
15. Jenner P (1995) The rationale for the use of dopamine agonists in Parkinson's disease. Neurology 45(Suppl 3):S6-S12.
16. 2 dopamine receptor mechanisms in dopaminergic behaviors. Clin Neuropharmacol 11:221-231.
17. Kontani H, Inoue T and Sakai T (1990a) Effects of apomorphine on urinary bladder motility in anesthetized rats. Jpn J Pharmacol 52:59-67.
18. Kontani H, Inoue T and Sakai T (1990b) Dopminergic receptor subtypes that induce hyperactive bladder response in anesthetized rats. Jpn J Pharmacol 54:482-486.
19. Kresis DS, Mastropietro CW, Rawji SS and Walters JR (1997) The response of subthalamic nucleus neurons to dopamine receptor stimulation in a rodent model of Parkinson's disease. J Neurosci 17:6807-6819.
20. Kuno S, Mizuta E, Sakamoto H and Nagasaka M (1992) Anti-parkinsonian profile of BAM-1110 in MPTP-induced parkinsonian monkeys. Mov Disord Suppl 7:66.
21. 2 agonists on neurogenic bladder in Parkinson's disease and MPTP-induced parkinsonian monkeys. Mov Disord Suppl 12:1.
22. Lewin RJ, Dillard GV and Porter RW (1967) Extrapyramidal inhibition of the urinary bladder. Brain Res 4:301-307.
23. Lieberman AN, Neophytides A, Leibowitz M, Gopinathan G, Pact V, Waker R, Goodgold A and Goldstein M (1983) Comparative efficacy of pergolide and bromocriptine in patients with advanced Parkinson's disease. Adv Neurol 37:95-108.
24. Nestler EJ (1994) Hard target: understanding dopaminergic transmission. Cell 79:923-926.
25. 2-dopaminergic receptors, muscarinic acetylcholinoceptors and β-adrenoceptors. Gen Pharmacol 19:463-466.
26. Pavlakis AJ, Siroky MG, Goldstein I and Krane RJ (1983) Neurourologic findings in Parkinson's disease. J Urol 129:80-83.
27. Rinne JO, Rinne JK, Laakso K, Lönnberg P and Rinne UK (1985) Dopamine D1 receptors in the parkinsonian brain. Brain Res 359:306-310.
28. Rinne UK (1985) Combined bromocriptine-levodopa therapy early in Parkinson's disease. Neurology 35:1196-1198.
29. Rinne UK (1989) Lisuride, a dopamine agonist in the treatment of early Parkinson's disease. Neurology 39:336-339.
30. Seeman T and Van Tol HHM (1994) Dopamine receptor pharmacology. Trends Pharmacol Sci 15:264-270.
31. Sillén U, Rubenson A and Hjälmås K (1981) On the localization and mediation of the centrally induced hyperactive bladder response to L-dopa in the rat. Acta Physiol Scand 112:137-140.
32. Umemiya M and Raymond LA (1997) Dopaminergic modulation of excitatory postsynaptic currents in rat neostriatal neurons. J Neurophysiol 78:1248-1255.
33. Yoshimura N, Sasa M, Yoshida O and Takaori S (1992) Dopamine D-1 receptor-mediated inhibition of micturition reflex by central dopamine from the substantia nigra. Neurourol Urodyn 11:535-545.
34. 1 receptor agonist SKF 38393 suppresses detrusor hyperreflexia in the monkey with parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Neuropharmacology 32:315-321.
35. Yoshimura N and De Groat WC (1997) Neural control of the lower urinary tract. Int J Urol 4:111-125.